, Tracking Stock Market Picks
Enter Symbol:
Infinity Pharmaceuticals, Inc. (INFI) [hlAlert]

down 19.07 %

Infinity Pharmaceuticals, Inc. (INFI) rated Buy

Posted on: Thursday,  Jul 12, 2007  9:25 AM ET by Jefferies & Co

Jefferies & Co rated Buy Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) on 07/12/2007, when the stock price was $11.27.
Since then, Infinity Pharmaceuticals, Inc. has lost 19.08% as of 01/25/2016's recent price of $9.12.
If you would have followed this Jefferies & Co's recommendation on INFI, you would have lost 19.07% of your investment in 3119 days.

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company?s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), based on the activity and safety data from a Phase I trial reported during the year ended December 31, 2008.

Our focus on growing and mid-sized companies enables us to identify unique investment ideas, which can make the difference in a tough market. Jefferies' research effort covers U.S. & International equity, high yield, convertibles, investment grade fixed income and post-reorganization securities, as well as special situations and quantitative research. The more than 120-person team of research professionals covers over 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes and dig deeper to provide in-depth, thought provoking, objective research. Our analysts use a variety of quantitative and qualitative tools, integrating field analysis, proprietary channel checks and ongoing dialogue with the managements of the companies they cover. We utilize the latest technologies to deliver a research product that is timely, differentiated, and tailored to each customer's needs. Regular client access to companies and their management teams is provided through a wide variety of Jefferies hosted industry conferences, company management meetings and on-site tours.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/12/2007 9:25 AM Buy
11.27 15.00
as of 8/27/2015
1 Week up  7.67 %
1 Month down  -22.05 %
3 Months down  -25.55 %
1 YTD down  -33.96 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy